These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

863 related items for PubMed ID: 26327145

  • 1. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP, D'Cruz DP.
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [Abstract] [Full Text] [Related]

  • 2. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

  • 3. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J, Furie R.
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [Abstract] [Full Text] [Related]

  • 4. Belimumab for systemic lupus erythematosus: a practice-based view.
    Parodis I, Axelsson M, Gunnarsson I.
    Lupus; 2013 Apr; 22(4):372-80. PubMed ID: 23553780
    [Abstract] [Full Text] [Related]

  • 5. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
    Poh YJ, Baptista B, D'Cruz DP.
    Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
    [Abstract] [Full Text] [Related]

  • 6. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG, Fusco BE.
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [Abstract] [Full Text] [Related]

  • 7. Update on belimumab for the management of systemic lupus erythematosus.
    Lutalo PM, D'Cruz DP.
    Expert Opin Biol Ther; 2014 Nov; 14(11):1701-8. PubMed ID: 25303323
    [Abstract] [Full Text] [Related]

  • 8. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008 Nov; 9(3):197-202. PubMed ID: 18457473
    [Abstract] [Full Text] [Related]

  • 9. Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?
    Runkel L, Stacey J.
    Expert Opin Biol Ther; 2014 Apr; 14(4):491-501. PubMed ID: 24490627
    [Abstract] [Full Text] [Related]

  • 10. Belimumab: targeted therapy for lupus.
    Chugh PK, Kalra BS.
    Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
    [Abstract] [Full Text] [Related]

  • 11. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
    Wiglesworth AK, Ennis KM, Kockler DR.
    Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
    [Abstract] [Full Text] [Related]

  • 12. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V, Zisman D, Pokroy-Shapira E, Molad Y, Elkayam O, Paran D.
    Scand J Rheumatol; 2016 Dec; 45(2):103-6. PubMed ID: 26515057
    [Abstract] [Full Text] [Related]

  • 13. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.
    Guzman M, Hui-Yuen JS.
    Drug Des Devel Ther; 2020 Dec; 14():2503-2513. PubMed ID: 32612353
    [Abstract] [Full Text] [Related]

  • 14. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D.
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [Abstract] [Full Text] [Related]

  • 15. Belimumab therapy in systemic lupus erythematosus.
    Zouali M, Uy EA.
    BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
    [Abstract] [Full Text] [Related]

  • 16. 10 Years of belimumab experience: What have we learnt?
    Levy RA, Gonzalez-Rivera T, Khamashta M, Fox NL, Jones-Leone A, Rubin B, Burriss SW, Gairy K, Maurik AV, Roth DA.
    Lupus; 2021 Oct; 30(11):1705-1721. PubMed ID: 34238087
    [Abstract] [Full Text] [Related]

  • 17. Belimumab for the management of systemic lupus erythematosus.
    Lutalo PM, D'Cruz DP.
    Expert Opin Biol Ther; 2012 Jul; 12(7):957-63. PubMed ID: 22646798
    [Abstract] [Full Text] [Related]

  • 18. Belimumab in the management of systemic lupus erythematosus - an update.
    Tesar V, Hruskova Z.
    Expert Opin Biol Ther; 2017 Jul; 17(7):901-908. PubMed ID: 28460578
    [Abstract] [Full Text] [Related]

  • 19. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 20. Post-marketing experiences with belimumab in the treatment of SLE patients.
    Askanase AD, Yazdany J, Molta CT.
    Rheum Dis Clin North Am; 2014 Aug; 40(3):507-17, viii. PubMed ID: 25034159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.